California Public Employees Retirement System Sells 7,649 Shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)

California Public Employees Retirement System lessened its holdings in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 3.6% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 204,132 shares of the biopharmaceutical company’s stock after selling 7,649 shares during the period. California Public Employees Retirement System owned 0.16% of Alnylam Pharmaceuticals worth $48,034,000 as of its most recent filing with the SEC.

Several other institutional investors also recently modified their holdings of the business. Regeneron Pharmaceuticals Inc. bought a new stake in shares of Alnylam Pharmaceuticals in the 4th quarter valued at about $1,045,822,000. Norges Bank bought a new position in Alnylam Pharmaceuticals during the 4th quarter worth approximately $577,941,000. Raymond James Financial Inc. acquired a new position in shares of Alnylam Pharmaceuticals in the 4th quarter worth approximately $65,295,000. Jennison Associates LLC bought a new stake in shares of Alnylam Pharmaceuticals in the 4th quarter valued at $61,160,000. Finally, Proficio Capital Partners LLC increased its position in shares of Alnylam Pharmaceuticals by 25,929.6% during the fourth quarter. Proficio Capital Partners LLC now owns 193,660 shares of the biopharmaceutical company’s stock worth $45,570,000 after buying an additional 192,916 shares during the period. Institutional investors own 92.97% of the company’s stock.

Alnylam Pharmaceuticals Stock Down 5.3 %

Alnylam Pharmaceuticals stock opened at $255.76 on Wednesday. Alnylam Pharmaceuticals, Inc. has a fifty-two week low of $141.98 and a fifty-two week high of $304.39. The company has a debt-to-equity ratio of 15.27, a quick ratio of 2.71 and a current ratio of 2.78. The firm’s 50-day simple moving average is $260.15 and its 200 day simple moving average is $260.51. The stock has a market cap of $33.27 billion, a PE ratio of -117.86 and a beta of 0.39.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last announced its earnings results on Thursday, February 13th. The biopharmaceutical company reported ($0.65) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.62) by ($0.03). Research analysts predict that Alnylam Pharmaceuticals, Inc. will post -1.7 EPS for the current fiscal year.

Insider Activity

In related news, CFO Jeffrey V. Poulton sold 967 shares of the stock in a transaction dated Friday, February 14th. The stock was sold at an average price of $255.17, for a total transaction of $246,749.39. Following the sale, the chief financial officer now owns 32,786 shares of the company’s stock, valued at approximately $8,366,003.62. This represents a 2.86 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Director Phillip A. Sharp sold 11,250 shares of the firm’s stock in a transaction that occurred on Thursday, January 23rd. The shares were sold at an average price of $275.00, for a total transaction of $3,093,750.00. The disclosure for this sale can be found here. Insiders sold a total of 71,234 shares of company stock valued at $19,958,097 in the last ninety days. 1.50% of the stock is currently owned by insiders.

Wall Street Analyst Weigh In

Several research firms recently issued reports on ALNY. Morgan Stanley boosted their target price on shares of Alnylam Pharmaceuticals from $275.00 to $284.00 and gave the company an “equal weight” rating in a report on Friday, February 14th. Wells Fargo & Company upped their target price on Alnylam Pharmaceuticals from $275.00 to $287.00 and gave the company an “equal weight” rating in a research report on Friday, March 21st. JPMorgan Chase & Co. upgraded Alnylam Pharmaceuticals from a “neutral” rating to an “overweight” rating and lifted their target price for the stock from $280.00 to $328.00 in a report on Monday, March 24th. HC Wainwright increased their price target on Alnylam Pharmaceuticals from $400.00 to $500.00 and gave the stock a “buy” rating in a report on Monday, February 24th. Finally, Chardan Capital reiterated a “buy” rating and issued a $300.00 price objective on shares of Alnylam Pharmaceuticals in a research note on Friday, March 21st. One equities research analyst has rated the stock with a sell rating, five have given a hold rating and twenty-one have assigned a buy rating to the stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $316.25.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.